Mabylon gets funding to advance human-derived antibodies for ALS
The Swiss biotechnology company Mabylon has received two research grants from Target ALS and the ALS Association…
Articles by Andrea Lobo, PhD
Clene granted in-person FDA meeting on CNM-Au8 for ALS
Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held…
Amprion wins $100K to study causes of sporadic ALS
Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral…
AcuraStem receives $4M grant to advance ASO treatment for ALS
AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development…
Qalsody can slow progression of SOD1-ALS, aid function: Study
Treatment with Qalsody (tofersen) substantially slowed disease progression and reduced markers of nerve damage in people with amyotrophic…
Nonprofit biotech develops tool to help ALS patients find clinical trials
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech, has developed a comprehensive resource designed to help people with…
ProJenX wins $1M ALS Association grant to test prosetin in patients
Biotechnology company ProJenX has received a $1 million grant from the ALS Association to support a portion of…
BrainStorm, FDA align on important aspects of upcoming NurOwn trial
BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing,…
Tiziana seeks ALS Association grant to test foralumab for ALS
Tiziana Life Sciences has applied for a grant from the ALS Association to fund an early-stage clinical trial…
Eli Lilly to develop, market ALS therapy for UNC13A function
Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for…